Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey D Barnes

Showing results (231-240 of 290) with videos related to

Pageof 29
Sort By:
Journal of the American College of Cardiology|August 28, 2024
Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific StatementMarc P Bonaca, Geoffrey D Barnes, Rupert Bauersachs, et al.
Journal of Thrombosis and Thrombolysis|June 23, 2023
Prediction of in-hospital deterioration in normotensive pulmonary embolism remains elusive: external validation of the calgary acute pulmonary embolism scoreS Nabeel Hyder, Sayhaan R Goraya, Kelsey A Grace, et al.
Journal of Thrombosis and Thrombolysis|September 19, 2022
Correction: Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID‑19 in the United States: a retrospective cohort studySteve Deitelzweig, Xuemei Luo, Jennifer L Nguyen, et al.
Journal of Thrombosis and Thrombolysis|June 28, 2018
Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI<sup>2</sup>) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trialsAndrew B Hughey, Xiaokui Gu, Brian Haymart, et al.
JAMA Internal Medicine|June 22, 2026
Multilevel Stewardship Intervention for Use of Anticoagulation-Antiplatelet TherapyJacob E Kurlander, David Parra, Von Moore, et al.
Journal of Thrombosis and Thrombolysis|April 30, 2022
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort studySteve Deitelzweig, Xuemei Luo, Jennifer L Nguyen, et al.
Circulation|October 5, 2019
Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart AssociationJay Giri, Akhilesh K Sista, Ido Weinberg, et al.
Journal of Thrombosis and Thrombolysis|August 18, 2023
Digital dashboards for oral anticoagulation management: a literature scoping reviewAaron S Wilson, Darren M Triller, Arthur Allen, et al.
Journal of Pharmacy Practice|December 28, 2021
Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation PatientsThane Feldeisen, Constantina Alexandris-Souphis, Brian Haymart, et al.
Blood Advances|January 4, 2018
Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulantsJordan K Schaefer, Suman L Sood, Brian Haymart, et al.
Pageof 29

Showing results (231-240 of 290) with videos related to

Sort By:
Pageof 29
Journal of the American College of Cardiology|August 28, 2024
Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific StatementMarc P Bonaca, Geoffrey D Barnes, Rupert Bauersachs, et al.
Journal of Thrombosis and Thrombolysis|June 23, 2023
Prediction of in-hospital deterioration in normotensive pulmonary embolism remains elusive: external validation of the calgary acute pulmonary embolism scoreS Nabeel Hyder, Sayhaan R Goraya, Kelsey A Grace, et al.
Journal of Thrombosis and Thrombolysis|September 19, 2022
Correction: Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID‑19 in the United States: a retrospective cohort studySteve Deitelzweig, Xuemei Luo, Jennifer L Nguyen, et al.
Journal of Thrombosis and Thrombolysis|June 28, 2018
Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI<sup>2</sup>) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trialsAndrew B Hughey, Xiaokui Gu, Brian Haymart, et al.
JAMA Internal Medicine|June 22, 2026
Multilevel Stewardship Intervention for Use of Anticoagulation-Antiplatelet TherapyJacob E Kurlander, David Parra, Von Moore, et al.
Journal of Thrombosis and Thrombolysis|April 30, 2022
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort studySteve Deitelzweig, Xuemei Luo, Jennifer L Nguyen, et al.
Circulation|October 5, 2019
Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart AssociationJay Giri, Akhilesh K Sista, Ido Weinberg, et al.
Journal of Thrombosis and Thrombolysis|August 18, 2023
Digital dashboards for oral anticoagulation management: a literature scoping reviewAaron S Wilson, Darren M Triller, Arthur Allen, et al.
Journal of Pharmacy Practice|December 28, 2021
Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation PatientsThane Feldeisen, Constantina Alexandris-Souphis, Brian Haymart, et al.
Blood Advances|January 4, 2018
Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulantsJordan K Schaefer, Suman L Sood, Brian Haymart, et al.
Pageof 29